Related Experiment Video
Updated: Dec 15, 2025
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
8.3K
Understanding the Pathogenesis Involved in Parkinson's Disease and Potential Therapeutic Treatment Strategies
Meenakshi Dhanawat1, Dinesh K Mehta1, Sumeet Gupta1
1M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, HR-133207, India.
Central Nervous System Agents in Medicinal Chemistry
|July 7, 2020
Summary
Advancements in Parkinson's disease (PD) treatment focus on neuroinflammation and neurodegeneration. New therapies target these mechanisms, offering personalized treatment options beyond symptomatic relief.
Area of Science:
- Neuroscience
- Pharmacology
- Neurology
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder characterized by neuronal loss, neuroinflammation, and Lewy body aggregates.
- Patients experience motor and non-motor symptoms, with current treatments primarily focusing on prophylaxis or symptom management.
- Levodopa is a primary symptomatic treatment but has limitations, necessitating combination therapies.
Purpose of the Study:
- To review recent advancements in Parkinson's disease therapeutics.
- To highlight neuroinflammation and neurodegeneration as key targets for novel therapeutic strategies.
- To discuss the identification of significant causes and therapeutic targets for PD.
Main Methods:
- Literature review of recent advancements in Parkinson's disease research.
- Analysis of therapeutic targets focusing on neuroinflammation and neurodegeneration.
- Evaluation of current and emerging drug regimens for Parkinson's disease.
Main Results:
- Significant progress has been made in understanding PD pathogenesis, leading to promising new therapies.
- Neuroinflammation and neurodegeneration are identified as crucial targets for intervention.
- Personalized treatment regimens, tailored to individual patient needs, are increasingly important.
Conclusions:
- Targeting neuroinflammation and neurodegeneration offers new avenues for Parkinson's disease treatment.
- Understanding disease mechanisms allows for the development of more effective therapeutic strategies.
- Individualized treatment approaches are essential for optimal management of Parkinson's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
830
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
830
01:15Parkinson's Disease: Overview
1.5K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.5K
01:22Alzheimer's Disease: Treatment
659
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
659
01:29Drugs Affecting Neurotransmitter Synthesis
2.0K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.0K
01:37Neural Regulation
42.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
42.8K
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
1.7K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
1.7K